ADHD Spokesperson, Celebrity Team Up Announcing VYVANSE For Adult ADHD Treatment

Advertisement
2008-07-24 08:37

Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has launched VYVANSE (lisdexamfetamine dimesylate) for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD). This launch of adult ADHD treatment follows the recent FDA approval of VYVANSE to treat ADHD in the adult population. VYVANSE is now available in U.S. pharmacies nationwide in six once-daily dosage strengths. To raise awareness of ADHD in adults and recognize the launch of VYVANSE for adults, Shire has partnered with celebrity designer Ty Pennington to shine the spotlight on living as an adult with ADHD. Pennington takes VYVANSE as part of his treatment plan to manage his ADHD symptoms so he can focus and get work done.

Pennington returns today to his hometown of Atlanta, where he will visit the Savannah College of Art and Design-Atlanta (SCAD-Atlanta) and announce the Daily Successes with ADHD Scholarship for an adult with ADHD who is pursuing an education or career in a creative field at SCAD-Atlanta. The $10,000 scholarship, sponsored by Shire, the maker of VYVANSE, will benefit an adult with ADHD who is enrolled in, or applying to, a graduate program at the art institution. The objective of the scholarship is to recognize achievements, and to motivate a student to continue to focus and achieve daily successes.

Pages

Advertisement
Subscribe to EmaxHealth on YouTube

Comments

As one of several adults treated with other amphetamine (either Dexedrine or Adderall) stims who agreed to test Vyvanse for ADD/ADHD, I can state that at least in our group (#10), this drug was at best a dud, at worst, promoted extreme aggression and depression. All participants reduced the use of their usual stims but because Vyvanse IS adderall or the mixed amphetamine salts compound, reactions between different chemicals was not a concern. NO one felt that one Vyvanse (no matter what dosage used) was "one-a-day". Every person noted a fall-off, however smooth, by 3PM. All persons felt more irritable and short-fused around 5PM and had to take their regular meds. Almost 60% of the group reported feelings during the Vyvanse-dosed pert of the day of heightened aggressive behavior and/or depression and 2 persons felt such despair that they had suicide ideations (something NEVER experienced on their usual amphetamine meds). Plus 100% of testers experienced dry mouth to varying degrees. Two persons experienced diuretic symptoms that interfered with their workday, although it is unknown whether this effect could be the result of attempts to alleviate the dry mouth. In 75% moderate to severe stomach ache and/or nausea was observed almost every day; and reduced appetite was noted by 100% of testers. All testers also experienced headaches shortly after taking the daily dose; 40% noted headaches in addition during random times throughout the day. Elevated BP (from their normal) were reported by 30% of the group. Finally only 2 persons were able to take Vyvanse for the entire 14-day period. Most persons withdrew by Day 7 (#6); one person withdrew Day 8; one person withdrew Day 11. NOT ONE PARTICIPANT SAID THAT THEY WANTED TO CHANGE FROM THEIR ORIGINAL AMPHETAMINE MEDS TO VYVANSE. THEY FELT THAT EVEN WITH ELIMINATING THE SIDE EFFECTS, THEY DID NOT OBSERVE ANY IMPROVEMENT IN THEIR ABILITY TO CONCENTRATE OR LEARN. (Note: this 14-day test was conducted completely unofficially, and only to see if Vyvanse lived up to the hype. All participants were and continue to be evaluated at least every 3 months by psychiatrists who legally prescribed said medications.) The Shire company better have LOTS of cash put away for the lawsuits that will show in about 6 months.

Pages